



Animal Health Catalogue

Hazardous drug safety devices





Hazardous drug safety devices

Protecting healthcare workers

With the increasing risk of hazardous drug exposure in the veterinary practice, medical devices protecting healthcare workers have become a priority.

Indeed, as shown in several studies¹⁻⁷, if not handled properly, exposure to hazardous agents can cause numerous problems such as skin irritations, cancer, reproductive health issues.

To help prevent occupational exposure to hazardous drugs, BD offers a range of products and solutions that provide safe handling of hazardous drugs from end-to-end: drug compounding, preparation, transport, delivery, administration and disposal.



BD PhaSeal™ System

- BD PhaSeal™ is an easy to learn and easy to use system
- BD PhaSeal™ makes it easy to live up to safety guidelines and obligations to the staff
- Clinically demonstrated to reduce personnel exposure to hazardous drugs⁸⁻¹²
- A protection for you and your staff when hazardous drugs are involved to avoid potential health risk with even limited or infrequent exposure⁸⁻¹²
- BD PhaSeal™ is designed with dry, leak-proof connections – preventing exposure when connecting and disconnecting from vials, syringes, IV bags and animal IV lines^{9,13-17}
- The system is based on three primary components: Protector, Injector and Connector. They come in a range of sizes to meet the specific requirements and preferences^{9,18,19}
- The sealed airtight chamber of the Protector captures aerosols and vapors while maintaining equal pressure in the vial during drug preparation^{9,18,19}
- The Injector ensures sealed drug transfer and “locks” into safe mode when the procedure is complete to prevent any risk of exposure^{9,18,19}
- Drug Vial Sterility maintained for up to 168 hours⁸



BD PhaSeal™ Protector – Drug Vial Access Device

Description	For drug vials with neck diameter of (mm)	Pressure Equalization Chamber Size (mL)	Color Code	Shelf Box/ Shipping case	Reference
Protector P14	13	20	Blue	50 / 200	515100
Protector P21	20	20	Red	50 / 200	515102
Protector P21 Multi	20	20	Red	250 (case)	515103
Protector P28	28	60	White	25 / 100	515104
Protector P50	20	50	Green	25 / 100	515105
Protector P50 Multi	20	50	Green	150 (case)	505106
Protector P53	32	50	Purple	25 / 100	515107
Protector P55 with plastic spike	20	50	Light Green	25 / 100	515117



BD PhaSeal™ Injector – Syringe Safety Device

Description	Protection cap	Shelf Box/ Shipping case	Reference
Injector Luer N30C for syringes with Luer connection	Red	50 / 200	515001
Injector Luer Lock N35C for syringes or IV bag with Luer Lock connection	Clear	50 / 200	515004
Injector Luer Lock N35C Multi for syringes or IV bag with Luer Lock connection	Clear	250 (case)	515005



BD PhaSeal™ Connector – Access Port

Description	Length (cm)	Priming volume (ml)	Shelf Box/ Shipping case	Reference
Connector Luer Lock C35	2.85	0.09	50 / 200	515200
Connector Luer Lock for use with needle-free ports with internal pistons C45	3.6	0.1	50 / 200	515202
Y-site connector extension tubing with built-in BD PhaSeal™ Connector C80	21	1.6	30 / 120	515304

BD PhaSeal™ Administration Products – IV Bag Access



Description	Length (cm)	Priming volume (ml)	Inline filter	Drops (ml)	Shelf Box/ Shipping case	Reference
Infusion Set C50	188	17.5	15µm	20	100 (case)	515300
Secondary Set C61	49	3.0	-	-	30 / 120	515302
L Connector C90	3.4	-	-	-	50 / 200	515305

BD PhaSeal™ Administration Products – Adaptors



Description	Shelf Box/ Shipping case	Reference
Infusion Adapter C70	50 (case)	515303
L Connector C90	50 / 200	515305
Infusion Adapter C100	50 / 200	515306
Infusion Adapter C100 Multipack	250 (case)	515307

1. Nyman HA, Jorgenson JA, Slawson MH. Workplace Contamination with Antineoplastic Agents in a New Cancer Hospital Using a Closed-System Drug Transfer Device. *Hosp Pharm.* 2007;42:219–225
2. Wick C., Slawson M.H., Jorgenson J.A., Tyler L.S. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. *Am J Health-Syst Pharm.* 2003;60(22):2314–20
3. Simon N, Vasseur M, Pinturaud M, et al. Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study. *PLOS ONE.* 2016;11(7):e0159052
4. Castiglia L, Miraglia N, Pieri M, et al. Evaluation of occupational exposure to antineoplastic drugs in an Italian hospital oncological department. *J Occup Health.* 2008;50:48–56
5. Turci R, Minoia R, Sottani C, et al. Occupational exposure to anti-neoplastic drugs in seven Italian hospitals. *J Oncol Pharm Practice.* 2011;17(4):320–332
6. Vandebroucke J., Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. *J Oncol Pharm Practice.* 2001;6(4):146–152
7. Ndaw S, Denis F, Marsan P, Rémy A, Robert A. Exposition professionnelle des personnels de santé hospitaliers aux médicaments cytotoxiques. *Biométrie et mesure de la contamination de surface. TF 255. Réf Santé Trav.* 2018;154:81–92
8. Microbial barrier performance testing. *Nelson Labs Reports 930942-S01, 986104-S01.1 Amended, 988476-S01*
9. NIOSH vapor containment test engineering report. *Doc#922940-ES-0125*
10. NIOSH Alert
11. ISOPP Standards of Practice
12. ONS Safe Handling of Hazardous Drugs, 3rd Edition
13. Fluorescent leakage testing. *Doc#922940-ES-0114*
14. Protector connection stick sameness memo
15. C100 connection stick sameness memo
16. Modified NIOSH DRAFT vapor containment test engineering report – 24hr infusion. *Doc#922940-ES-0127*
17. Modified NIOSH DRAFT vapor containment test engineering report – 10Punctures. *Doc#922940-ES-0129*
18. Vapor leakage test with titanium tetrachloride. *Doc#922940-ES-0115*
19. Vial adapter pressure loss during assembly. *Doc#922940-ES-0137*

BD Switzerland Sàrl, Terre Bonne Park – A4, Route de Crassier 17, 1262 Eysins, Switzerland
 Tel: +41 21 556 30 00

bd.com

© 2019 BD. BD and the BD Logo are trademarks of Becton, Dickinson and Company. CF04131

